10x Genomics revenue and financials
$80.66Change from previous close: −17.47%Absolute change: −$17.08
In the fiscal year ended December 2025, 10x Genomics reported revenue of $642.82M (+5.25% year over year). The net loss was $43.54M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.25%
- 2025 vs 2024
- Net margin
- -6.8%
- 2024: -29.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 1,041 | 919 | 965 | 1,029 | 1,019 | 929 | 606 | — |
| Current assets | 684 | 584 | 596 | 635 | 748 | 774 | 481 | — |
| Cash and equivalents | 474 | 344 | 359 | 220 | 587 | 664 | 424 | 47.9 |
| Short-term investments | 49.4 | 49.3 | 29.4 | 210 | — | — | — | — |
| Receivables | 82.5 | 88.5 | 115 | 104 | 85.3 | — | — | — |
| Inventory | 56.3 | 83.1 | 73.7 | 81.6 | 60.0 | — | — | — |
| Net property, plant and equipment | 287 | 310 | 345 | 359 | 230 | — | — | — |
| Goodwill | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 | — | — | — |
| Other intangible assets | 62.3 | 15.7 | 16.6 | 22.9 | 25.4 | — | — | — |
| Current liabilities | 153 | 118 | 127 | 131 | 110 | 118 | 63.0 | — |
| Accounts payable | 12.7 | 12.9 | 15.7 | 21.6 | 17.4 | — | — | — |
| Long-term debt | — | — | — | — | — | 0.0 | 29.7 | — |
| Total debt | 84.4 | 82.6 | 95.4 | 95.2 | — | — | — | — |
| Total liabilities | 245 | 209 | 224 | 223 | 201 | 190 | 186 | — |
| Total equity (incl. minority) | 796 | 710 | 741 | 806 | 818 | — | — | — |
| Retained earnings | -1,511 | -1,467 | -1,284 | -1,029 | -863 | — | — | — |